These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 37759475)

  • 1. Therapeutic Oligonucleotides: An Outlook on Chemical Strategies to Improve Endosomal Trafficking.
    Mangla P; Vicentini Q; Biscans A
    Cells; 2023 Sep; 12(18):. PubMed ID: 37759475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyaluronan-based delivery of therapeutic oligonucleotides for treatment of human diseases.
    Ossipov DA
    Expert Opin Drug Deliv; 2019 Jun; 16(6):621-637. PubMed ID: 31072142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemical Manipulation of the Endosome Trafficking Machinery: Implications for Oligonucleotide Delivery.
    Juliano RL
    Biomedicines; 2021 May; 9(5):. PubMed ID: 34063104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endosomal escape cell-penetrating peptides significantly enhance pharmacological effectiveness and CNS activity of systemically administered antisense oligonucleotides.
    Dastpeyman M; Sharifi R; Amin A; Karas JA; Cuic B; Pan Y; Nicolazzo JA; Turner BJ; Shabanpoor F
    Int J Pharm; 2021 Apr; 599():120398. PubMed ID: 33640427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Site Selective Antibody-Oligonucleotide Conjugation via Microbial Transglutaminase.
    Huggins IJ; Medina CA; Springer AD; van den Berg A; Jadhav S; Cui X; Dowdy SF
    Molecules; 2019 Sep; 24(18):. PubMed ID: 31509944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous inhibition of endocytic recycling and lysosomal fusion sensitizes cells and tissues to oligonucleotide therapeutics.
    Finicle BT; Eckenstein KH; Revenko AS; Anderson BA; Wan WB; McCracken AN; Gil D; Fruman DA; Hanessian S; Seth PP; Edinger AL
    Nucleic Acids Res; 2023 Feb; 51(4):1583-1599. PubMed ID: 36727438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endosomal escape of RNA therapeutics: How do we solve this rate-limiting problem?
    Dowdy SF
    RNA; 2023 Apr; 29(4):396-401. PubMed ID: 36669888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delivery of RNA Therapeutics: The Great Endosomal Escape!
    Dowdy SF; Setten RL; Cui XS; Jadhav SG
    Nucleic Acid Ther; 2022 Oct; 32(5):361-368. PubMed ID: 35612432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The delivery of therapeutic oligonucleotides.
    Juliano RL
    Nucleic Acids Res; 2016 Aug; 44(14):6518-48. PubMed ID: 27084936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delivery of Oligonucleotide Therapeutics: Chemical Modifications, Lipid Nanoparticles, and Extracellular Vesicles.
    Bost JP; Barriga H; Holme MN; Gallud A; Maugeri M; Gupta D; Lehto T; Valadi H; Esbjörner EK; Stevens MM; El-Andaloussi S
    ACS Nano; 2021 Sep; 15(9):13993-14021. PubMed ID: 34505766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative Measurement of Cytosolic and Nuclear Penetration of Oligonucleotide Therapeutics.
    Deprey K; Batistatou N; Debets MF; Godfrey J; VanderWall KB; Miles RR; Shehaj L; Guo J; Andreucci A; Kandasamy P; Lu G; Shimizu M; Vargeese C; Kritzer JA
    ACS Chem Biol; 2022 Feb; 17(2):348-360. PubMed ID: 35034446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue-Specific Delivery of Oligonucleotides.
    Xia X; Pollock N; Zhou J; Rossi J
    Methods Mol Biol; 2019; 2036():17-50. PubMed ID: 31410789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progress toward oligonucleotide therapeutics: pharmacodynamic properties.
    Crooke ST
    FASEB J; 1993 Apr; 7(6):533-9. PubMed ID: 7682523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intracellular Trafficking and Endosomal Release of Oligonucleotides: What We Know and What We Don't.
    Juliano RL
    Nucleic Acid Ther; 2018 Jun; 28(3):166-177. PubMed ID: 29708838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver as a target for oligonucleotide therapeutics.
    Sehgal A; Vaishnaw A; Fitzgerald K
    J Hepatol; 2013 Dec; 59(6):1354-9. PubMed ID: 23770039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A physiologically-based pharmacokinetic model to describe antisense oligonucleotide distribution after intrathecal administration.
    Monine M; Norris D; Wang Y; Nestorov I
    J Pharmacokinet Pharmacodyn; 2021 Oct; 48(5):639-654. PubMed ID: 33991294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oligonucleotide therapeutics: chemistry, delivery and clinical progress.
    Sharma VK; Watts JK
    Future Med Chem; 2015; 7(16):2221-42. PubMed ID: 26510815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug Metabolism and Pharmacokinetics of Antisense Oligonucleotide Therapeutics: Typical Profiles, Evaluation Approaches, and Points to Consider Compared with Small Molecule Drugs.
    Takakusa H; Iwazaki N; Nishikawa M; Yoshida T; Obika S; Inoue T
    Nucleic Acid Ther; 2023 Apr; 33(2):83-94. PubMed ID: 36735616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel endosomolytic compounds enable highly potent delivery of antisense oligonucleotides.
    Bost JP; Ojansivu M; Munson MJ; Wesén E; Gallud A; Gupta D; Gustafsson O; Saher O; Rädler J; Higgins SG; Lehto T; Holme MN; Dahlén A; Engkvist O; Strömstedt PE; Andersson S; Edvard Smith CI; Stevens MM; Esbjörner EK; Collén A; El Andaloussi S
    Commun Biol; 2022 Mar; 5(1):185. PubMed ID: 35233031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular uptake and intracellular trafficking of oligonucleotides.
    Juliano RL; Carver K
    Adv Drug Deliv Rev; 2015 Jun; 87():35-45. PubMed ID: 25881722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.